anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
For the purpose of determining whether or not the activation of hepatic NF-κB is involved in the onset of metastatic tumors, a liver metastatic model induced in the spleen is used. When IKKβ is lacked in both hepatocytes and hematopoietically-derived cells, the onset of tumors is remarkably decreased. A tumor cell activates an adjacent bone marrow cell (Kupffer cell) to produce a mitogen such as interleukin (IL)-6, and the mitogen accelerates the proliferation of a tumor and neovascularization. The production of the mitogen depends on NF-κB in hematopoietically-derived Kupffer cells. In addition, the treatment with an anti-IL-6 receptor antibody can decrease the level of the onset of a metastatic tumor. Consequently, it is demonstrated that the metastasis of tumors depends on inflammations, and it is also demonstrated that the proinflammatory mediation which targets at Kupffer cells is useful in the chemoprevention of metastatic tumors. It is also demonstrated that the inhibition of an IKKβ/NF-κB signaling pathway, particularly IL-6, can be employed as an anti-metastasis agent.
A composition includes a plurality of amino acids. The plurality of amino acids includes at least one essential amino acid and at least one non-essential amino acid. The plurality of amino acids also includes at least one branch-chain amino acid. The composition also includes a source of carbohydrates. The compositions also includes purified water. The plurality of amino acids comprises about 1 wt % of the composition. A composition includes a plurality of amino acids, sodium citrate, sodium chloride, potassium phosphate, flavoring, a source of carbohydrates, and purified water. In some embodiments of the composition, the plurality of amino acids includes alanine, arginine, aspartate, cystine, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonin, tryptophan, tyrosine, and valine.
Alzheimer disease (also termed Alzheimer's disease or AD) is a progressive and devastating neurodegenerative disorder with a poor prognosis, and for which no curative treatment is available yet With respect to diagnosis, a huge amount of work has been performed with the aim to identify relevant markers for diagnosing AD, ideally the different stages of progression thereof. It is admitted in the art that development of AD involves both genetic factors and non- genetic factors. This explains why the search for biomarkers includes identification of genetic and non-genetic biomarkers. Further, even though the field of Alzheimer disease research has rapidly developed over the last decade, there is still a lack of disease-modifying therapies. Thus, it remains a great need for methods allowing a diagnosis of the Alzheimer disease. The present disclosure relates to methods relating to the diagnosis of AD, including the development stage of AD, as well as methods for monitoring the efficiency of a (candidate) therapeutic treatment of AD, which methods take benefit from the inventors' findings that AD nucleated cells, especially AD skin fibroblasts, show one or more perinuclear crowns of the auto-phosphorylated form of the ATM protein.
PROBLEM TO BE SOLVED: To provide an agent for improving intestinal bacterial flora and a composition for improving intestinal bacterial flora containing the agent for improving intestinal bacterial flora using ethyl-α-glucoside by notice of the effect for improving intestinal bacterial flora performed by ethyl-α-glucoside being contained in a refined sake. SOLUTION: The agent for improving intestinal bacterial flora consists of ethyl-α- glucoside. Further, the composition for improving intestinal bacterial flora containing ethyl-α-glucoside as the agent for improving intestinal bacterial flora. In this case, the agent for improving intestinal bacterial flora consists of ethyl-α-glucoside performs the following functions as follows: (1) It promotes proliferation of intestinal benign bacteria such as Bifidobacterium bifidum, Lactobacilus acidophilus and the like. (2) It inhibits proliferation of intestinal malignant bacteria such as Welsh bacillus, Escherichia coli, Staphylococci and the like.  When formulating a food containing ethyl-α-glucoside having excellent effect for improving intestinal bacterial flora, then similarly excellent effect for improving intestinal bacterial flora shown by ethyl-α- glucoside itself can also be shown.
Data will be collected during heel blood sampling for blood sugar control from newborns randomly assigned to the control group. Babies in the control group will not be allowed to smell breast milk or listen to white noise.The newborn in the control group will continue to receive routine care.Camera recording will start 5 minutes before the procedure and lasting 5 minutes after the procedure.
The invention belongs to the technical field of traditional Chinese medicine and particularly relates to a traditional Chinese medicine prescription applied to preoperative adjuvant therapy of lung cancer. The traditional Chinese medicine prescription is composed of, by weight, 15-20 parts of fructus hippophae, 15-20 parts of rhizoma pinelliae, 10-15 parts of cortex magnoliae officinalis, 10-15 parts of all-grass of gynuracrepidioides benth.[crassoucephalumcrepidioides (benth.) S.moore], 5-10 parts of whitebackleaf mallotus leaves, 10-15 parts of rhizoma acorus calamus, 10-15 parts of common perilla fruits, 10-15 parts of fiveleaf akebia fruits, 5-10 parts of fructus citri sarcodactylis, 15-20 parts of pepperweed seeds, 10-15 parts of creeping sage herbs, 10-15 parts of roots of gerbera delauayi franch., 10-15 parts of chuanxiong rhizomas, 5-10 parts of rhizoma corydalis, 5-10 parts of black nightshade herbs, 5-10 parts of herba scutellariae barbatae and 5-10 parts of spreading hedyotis herbs. The Traditional Chinese medicine prescription has the advantages that traditional Chinese medicine used in the prescription meets the specification of the pharmacopoeia of the People's Republic of China and is safe and reliable. All the medicinal raw materials are compatible with one another and achieve the effects of promoting dampness elimination and phlegm removal, tonifying the spleen, regulating qi and the like, and the traditional Chinese medicine prescription is definite in treatment effect, quick in effectiveness, free of toxic or side effect and the like when used for treating phlegm-dampness and lung-obstruction type lung cancer.
These patients will receive serratus anterior plane block. The block will be performed while the patient is in the supine position by using a linear Ultrasound probe of high frequency (6-13 MHz) after sheathing. The probe will be placed over the mid-clavicular region of the thoracic cage in a sagittal plane. The ribs will be counted inferiorly and laterally, until the 5th rib is identified in the midaxillary line. The latissimus dorsi (superficial and posterior) , teres major (superior) and serratus muscles (deep and inferior) will be then easily identifiable by U/S overlying the fifth rib.
OBJECTIVE: To investigate the mid-term efficacy and patency rate of TurboHawk peripheral plaque excision system in the treatment of femoral popliteal artery lesions with different Global Limb Anatomic Staging System (GLASS) grades.
METHODS: The clinical data of 141 patients with femoral popliteal arteriosclerosis obliterans who were treated with TurboHawk from January 2018 to July 2022 in our institution were retrospectively analyzed. There were 109 male patients and 32 female patients. Recordings were made of the patient's symptoms of limb ischemia, technical success rate, primary patency rate of target vessels, ankle brachial index (ABI), GLASS grades, postoperative complications, and a statistical analysis with the patient's preoperative treatment was conducted.
RESULTS: All patients had improved limb ischemia symptoms to varying degrees after surgery, with a technical success rate of 100% (femoral artery puncture and superficial femoral artery recanalization) without bleeding, hematoma, pseudoaneurysm, arteriovenous fistula or other complications. The follow-up period was 1-24 months, during which the severity of claudication, resting pain, and toe ulcers significantly improved. The primary patency rate of the target vessel was 98.58% (139/141), and the ABI significantly increased on the second day, three months, and six months after surgery compared to before surgery. No major adverse events were found during follow-up. The patency rates at 1, 6, 12 and 24 months after intervention were 100%, 80%, 75% and 60% respectively.
CONCLUSION: The mid-term efficacy and patency rate of TurboHawk in the treatment of femoral popliteal artery lesions with GLASS I patients have the best mid-term prognosis, the highest mid-term survival rate, and the highest vascular patency. The plaque removal system has proven to be an effective treatment for individual localized chronic total occlusion lesions. Additionally, the TurboHawk system provides a safe and minimally invasive treatment alternative for superficial femoral artery conditions, achieving significant therapeutic results within a brief period.
Chemotherapy plus pembrolizumab plays a significant role in standard of care frontline treatment in R/M HNSCC and there is a need for improvement in outcomes with this combination therapy. This trial importantly will test a new dosing and sequence of pembrolizumab and chemotherapy, with the primary goal of improving efficacy but secondarily also has the potential to be better tolerated than standard dosing. Additionally, this trial may have applicability to other solid tumor types where chemotherapy and anti-PD-1 mAb are currently combined. Based on current data showing that current repetitive frequent dosing of chemotherapy may lead to immunosuppression and a detrimental effect on the prolonged duration of response expected from pembrolizumab, and that chemotherapy efficacy may be higher after anti-PD-1 mAb therapy, this trial will test a new sequence starting with pembrolizumab with less frequent dosing of chemotherapy (pulsed dose) to maximize synergy and improve efficacy. Specifically, patients will be treated with pembrolizumab 200 mg IV q3w with carboplatin/paclitaxel given starting with cycle 2 of pembrolizumab and continued thereafter every 3rd cycle of pembrolizumab (q9w) for a total of 4 cycles of carboplatin/paclitaxel. After completion of the 4th cycle of carboplatin/paclitaxel, pembrolizumab maintenance will be continued at 400 mg IV q6w for 12 cycles for a total of 2 years of therapy. Carboplatin/paclitaxel is being used as the chemotherapy doublet in this trial because there is more data for immunogenicity and higher efficacy post anti-PD-1 with taxanes, the potential to be better tolerated than infusional 5-fluorouracil (5FU), and physician preference for this chemotherapy backbone including in our Hillman network. Importantly, prior to the immunotherapy era, a phase III trial compared platinum/taxane to platinum/5FU in R/M HNSCC and found no difference in efficacy between these regimens, and outcomes in combination with pembrolizumab are comparable.
Participants with exacerbation of schizophrenia may be included. The study will be composed of 2 periods: Period 1 (the double-blind, placebo-controlled, efficacy and safety period) and Period 2 (open-label long term safety period). For each participant, the duration of Period 1 will be 8 weeks, and the duration of Period 2 will be up to 48 weeks. In Period 1, participants will be randomized to one of 3 TV-44749 treatment groups or a placebo group in a 1:1:1:1 ratio. All participants will be randomized again to one of the TV44749 treatment groups in a 1:1:1 ratio for Period 2. The end-of-treatment and follow-up visits will be at 4 and 8 weeks after the last dose of investigational medicinal product administration, respectively.
It will be a randomized controlled trial. The stroke patients aged between 30-70 years will be included in this study. Participants will be selected with non-probability convenience sampling technique. Participants will be randomly allocated into two groups by lottery method i.e experimental group and control group. The experimental group will receive proprioceptive neuromuscular technique (contract relax-10 repetition) (5-min) and electrical muscle stimulation(10 min) as 15 min session 3 times a week for four weeks while the control group will receive only conventional therapy. The outcome measure will be calculated by modified barthel index, modified ashworth scale and wolf motor function test.
The administration of micro-organisms to improve the human health was already promoted by the Nobel prizewinning scientist Eli Metchnikoff in the beginning of the 20th century. However, it took several decades for this subject to become a topic of interest in medicine. At this moment these micro-organisms are called "probiotics" and defined as "living microorganisms which, when administered in adequate amounts, confer a health benefit for the host" (http://www.who.int/foodsafety/publications/fs_management/en/probiotics.pdf). Over the past decade probiotics have been extensively investigated from the perspective of oral health. It was shown that probiotics have the capacity to reduce mutans streptococci counts in saliva and/or plaque during their usage, that they have a positive influence on bad breath and that they can improve the results of scaling and root planing in periodontitis patients. A positive effect of probiotic usage on plaque accumulation and gingivitis measurements in gingivitis patients was also shown.To the investigators knowledge, at this moment no trials are available describing the effect of other probiotic genera on gingivitis. Since it is clear that probiotic effects are strain, dosage and mode of application dependent, the aim of this study was to evaluate the use of a probiotic toothpaste, mouthwash and toothbrush cleaner with Bacillus subtilis, Bacillus megaterium, and Bacillus pumulus versus a placebo in patients with generalized gingivitis.
The therapeutic arm will include subjects with diagnosed symptomatic VTE (PE and/or DVT). Each subject will receive an Adient absorbable filter to help prevent a subsequent PE. All study subjects will return to the investigation site for the Follow-up Visits at Week 2 (±3 days), Week 10 (±1 week) and Month 9 (±2 weeks). Subjects will be interviewed and examined at each follow-up visit to perform safety and filter status evaluations.
A polygenic nucleic acid construct comprising at least two nucleotide sequences selected from nucleotide sequences encoding a WbbL antigen having the amino acid sequence of SEQ ID NO 1, a CFP-10 antigen having the amino acid sequence of SEQ ID NO 2, a PPE18 antigen having the amino acid sequence of SEQ ID NO 3, and a PE13 antigen having the amino acid sequence of SEQ ID NO 4. The construct can comprise all four antigens. The nucleotide sequences can be separated by linkers. The linkers can be a glycine-serine flexible linker, a glycine flexible linker, and a 2A-derived peptide. The construct can comprise a leader nucleotide sequence encoding a secretory peptide signal. A further aspect is an mRNA construct transcribed from the nucleic acid construct. The mRNA can be capped at the 5’ end. The mRNA can include modified nucleotides (e.g., N1-methyl-pseudouridine and pseudouridine). A further aspect is a lipid nanoparticle comprising the mRNA construct. A further aspect is a Mycobacterium tuberculosis vaccine composition comprising the polygenic nucleic acid construct, the mRNA construct, or the lipid nanoparticle.
Recent findings in humans suggest that motor sequences are represented in the premotor cortex once learned. Studies in animal models have also shown that the premotor cortical areas encode sequence-specific information. However, it is currently unknown if premotor cortical areas are involved in the acquisition or consolidation of sequences in humans. In this project, the investigators will evaluate the functional contributions of human premotor cortex to sequence learning. The primary overarching research objective is to determine the brain regions causally involved in motor skill acquisition and consolidation. The main hypothesis is that disrupting premotor cortex activity during motor sequence learning will reduce the acquisition and consolidation of the skill. Transcranial magnetic stimulation (TMS) will be used to temporarily disrupt activity of premotor cortex or primary motor cortex, and skill learning will be assessed in both groups. A sham stimulation group, where participants will feel the coil on their head and hear the click of the TMS pulses but not actually receive stimulation to the brain, will be used as a control. Participants will be randomly assigned to be in the premotor cortex, primary motor cortex, or sham stimulation group. Participants may be asked to undergo a Magnetic Resonance Imaging (MRI) scan at Wesley Woods prior to TMS testing, which will occur at the Emory Rehabilitation Hospital. The MRI scan would be used to help target TMS to the intended brain area. Participants will be recruited using flyers around the local community. Consent forms will be provided with ample time for the participant to read it over and ask any questions that may arise. Participants will be compensated for their time. The proposed work will be the first to evaluate the causal role of premotor cortex in motor sequence learning in humans. Findings from this project are expected to inform the design and application of therapeutic interventions that improve motor functioning and learning in clinical populations.
MBI will be performed in 52 subjects after an overnight fast with 4-6 mCi Tc-99m sestamibi. The subject will receive the usual Mayo gown for breast imaging. A skin temperature sensor will be taped to the anterior of one breast and skin temperature will be recorded. The subject will be asked to sit for 15 minutes in the waiting room prior to injection of the Tc-99m sestamibi. Just prior to injection, skin temperature will be recorded again. After completion of the first study the subject will then be given a warm towel robe and a small heating pad to be placed over the chest area. After 30 minutes, skin temperature will be recorded again immediately prior to injection of the second dose of Tc-99m sestamibi. The second MBI study will then be performed.
Participants will receive intravenous (IV) tobemstomig every three weeks (Q3W) on Day 1 of each 21-day cycle. Participants will also receive oral (PO) axitinib twice daily (BID).
Crohn's disease (CD) progresses with periods of remission and exacerbations. During exacerbations, chronic inflammation leads to tissue destruction. As a result, intestinal fibrosis may develop in response to the ongoing inflammatory process. Fibrosis in CD should be considered the result of the response of the intestinal wall (over) to the presence of inflammation in the deep structures of the intestinal wall. In the absence of ideal noninvasive methods, endoscopic evaluation in combination with biopsy, histopathological analysis, stool analysis, and blood analysis remains the gold standard for assessing both inflammation and fibrosis in CD. On the contrary, the ability to identify markers of intestinal fibrosis would help to develop new diagnostic and therapeutic methods to detect early stages of fibrosis. It is speculated that miRNAs may, in the future, become biomarkers for early noninvasive diagnosis in the treatment of intestinal fibrosis. The purpose of this review is to summarise existing diagnostic methods for Crohn's disease and present recent scientific reports on molecular testing.
PURPOSE:To provide a home medical data controlling apparatus which can prevent a failure of mediation, measurement, and like and also prevent irregularity of medication time, measurement time, and the like. CONSTITUTION:When a reservation time is set, it is judged whether the present time coincides with a medication time or not. When the present time coincides with the medication time, a buzzer sound is generated for five times. A check is subsequently made to see if the present time coincides with a measurement time, and if yes, the buzzer sound is rung for ten times. When the setting of the reservation time is not cancelled, such a procedure is repeated. When the setting is cancelled, the process is finished.
In this study, patients will be observed who are planned to be treated an E-nside TAAA Multibranch Stent Graft System for endovascular repair of a degenerative, atherosclerotic thoracoabdominal aortic aneurysm. The E-nside TAAA Multibranch Stent Graft will be implanted at the discretion of the treating physician. Participating physicians will be asked to provide their observations collected during routine care for patients he/she had decided to treat with the E-nside TAAA Multibranch Stent Graft System. Informed consent of the patients to allow the use of their clinical records for the purpose of this observational study will be obtained before data are being collected. Patient data will be documented in an eCRF at the following time points: Pre-operative planning, intervention(s), discharge(s) from hospital, 30 days, 3-6 and 12 months follow-up. The period of data collection will be approximately 12 months (depending on the time point of the 12 months FU visit) from the index procedure for each patient. A 100% source data verification will be performed regarding patient information and consent, criteria of patients to be documented, pre-operative planning, intervention(s), treatment results, adverse events, death, and reintervention. Complete DICOM image files of the CT scans will be sent to a CoreLab for independent second evaluation.
A sieve guide assembly and a method of fractionation using a sieve guide assembly comprising a circular sieve screen (190) and a sieve guide 310 mountable in a fractionating device, wherein the fractionating device comprises a drive adapted for: (i) in combination with a sieve screen without a sieve guide, inducing a lateral flow of granules defining lateral streamlines 31a. 1. 31b. 1, 31c. 1, 31d.1 and an orbital flow defining orbital streamlines 31a.2. 31b.2, 31c.2, 31d.2, 31d.3 on the sieve screen (190), and (ii) in combination with the sieve guide assembly, inducing a guided lateral flow of granules defining guided lateral streamlines (331.3) and a central guided orbital flow defining central orbital streamlines (331.2) on the sieve screen (190), whereby the sieve guide assembly is adapted to provide a uniform, controlled and effective exposure of the granules to the sieve screen.
The training program will be conducted in accordance with the recommendations of the American College of Sports Medicine. All training sessions will be preceded by stretching of large muscle groups and heating (5 minutes) and at the end by cool down and stretching (5 minutes). The program will consist of 24 weeks with three sessions per week on alternate days. The aerobic training will be continuous, with an increment of 10 minutes in duration every 4 weeks. The intensity will be prescribed according to ventilatory threshold, characterized by the highest intensity of physical exertion fully maintained by aerobic energy pathways. The intensity control was done by means of the heart rate value obtained at ventilatory threshold. The home-based exercise group exercise at home with telephone follow-up weekly and once a month will be held at the training center under the supervision of a physical education teacher.